GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences total debt 1990–2026

Gilead Sciences's total debt was 26.23B USD on 30 September 2026, up 5.2% on a year before. At the end of fiscal year 2025 it was 24.94B USD.

Last updated 9 Nov 2026 · Next report 9 Feb 2027

Total debt

Growth

Fiscal yearPeriod endingTotal debtGrowthCash and short-term investmentsNet cashDebt to equity
Latest quarter30 Sept 202626.23B+5.17%6.44B-19.79B2.01
FY202531 Dec 202524.94B-6.65%9.61B-15.32B1.10
FY202431 Dec 202426.71B+6.90%11.57B-15.14B1.38
FY202331 Dec 202324.99B-0.96%7.26B-17.72B1.09
FY202231 Dec 202225.23B-5.49%6.39B-18.85B1.19
FY202131 Dec 202126.70B-14.99%6.52B-20.18B1.27
FY202031 Dec 202031.40B+27.69%7.41B-23.99B1.73
FY201931 Dec 201924.59B-9.99%24.35B-241.00M1.09
FY201831 Dec 201827.32B-18.54%30.09B2.77B1.28
FY201731 Dec 201733.54B+27.31%25.51B-8.03B1.64
FY201631 Dec 201626.35B+19.46%11.90B-14.45B1.39
FY201531 Dec 201522.06B+77.81%14.61B-7.45B1.19
FY201431 Dec 201412.40B+86.92%10.13B-2.28B0.80
FY201331 Dec 20136.64B-19.31%2.13B-4.50B0.58
FY201231 Dec 20128.22B+8.11%1.86B-6.36B0.88
FY201131 Dec 20117.61B+118.29%9.90B2.29B1.13
FY201031 Dec 20103.48B+177.90%2.10B-1.39B0.59
FY200931 Dec 20091.25B+8.08%1.66B402.98M0.20
FY200831 Dec 20081.16B-11.56%1.79B629.82M0.27
FY200731 Dec 20071.31B-7.00%1.17B-139.91M0.38
FY200631 Dec 20061.41B+368.86%936.85M-473.74M0.78
FY200531 Dec 2005300.86M+72,395.42%2.31B2.01B0.10
FY200431 Dec 2004415.00K-99.88%1.25B1.25B0.00
FY200331 Dec 2003345.46M-41.98%707.00M361.54M0.34
FY200231 Dec 2002595.47M+136.41%942.37M346.91M1.04
FY200131 Dec 2001251.88M-1.33%582.85M330.97M0.56
FY200031 Dec 2000255.27M+190.16%512.88M257.61M0.73
FY199931 Dec 199987.98M-13.32%294.39M206.42M0.30
FY199831 Dec 1998101.50M+3,071.88%101.10M-400.00K0.30
FY199731 Dec 19973.20M-50.77%32.00M28.80M0.01
FY199631 Dec 19966.50M+1.56%132.00M125.50M0.02
FY199531 Dec 19956.40M-23.81%27.40M21.00M0.04
FY199431 Dec 19948.40M+366.67%30.40M22.00M0.10
FY199231 Dec 19921.80M+80.00%2.10M300.00K0.01
FY199131 Dec 19911.00M+25.00%87.90M86.90M0.01
FY199031 Dec 1990800.00K—10.30M9.50M0.08

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Total debt counts commercial paper, term debt and lease liabilities.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Stock buybacks,Balance sheet

Common questions about Gilead Sciences's debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.